Loading live market data…

Impinj, Inc.

NASDAQ:PI

$144.6 USD

-$1.42 (-0.97%)

Volume
247.7K
Average Volume
477.73K
Market Capitalization
$4.4B
P/E Ratio
-159.29
Dividend Yield
0.00%
Price Target
$175.00
Year High
$247.06
Year Low
$87.36
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$9.20
Source Headline
Impinj to Announce Second-Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Impinj to Announce Second-Quarter 2026 Financial Results.

businesswire.com - 2026-07-06 16:15:00

Director Sells 33,000 Impinj Shares Worth $4.6 Million

33,412 shares were sold indirectly on June 4, 2026, with an estimated transaction value of ~$4.57 million based on the reported price of $136.84 per share. This sale represented 3.63% of Sylebra Capital LLC's indirect holdings in Impinj, reducing total indirect ownership from 921,467 to 888,055 shares.

fool.com - 2026-06-30 06:44:01

Director Sells 45,000 Impinj Shares Worth $6.4 Million

45,037 shares were indirectly sold for a total transaction value of ~$6.4 million, based on a weighted average price of $141.87 per share during June 2–3, 2026. The sale represented 4.66% of Sylebra Capital LLC's indirect holdings, reducing indirect ownership from 967,000 to 921,467 shares; direct holdings remained at zero.

fool.com - 2026-06-27 09:36:01

Intel vs. Impinj: Which Technology Stock Is a Better Buy in 2026?

Intel is aggressively expanding its foundry business and AI accelerator offerings to diversify beyond traditional PC and data center chips. Impinj maintains a specialized lead in RAIN RFID technology, though its revenue remains highly concentrated among a small number of partners.

fool.com - 2026-06-18 06:30:01

Insiders Are Selling These 3 Stocks—Should Investors Be Concerned?

Insider sales are hitting two massive stocks in industrials and retail, as well as a small-cap chip stock. Across these names, insiders are sending bearish signals, but their severity differs meaningfully.

marketbeat.com - 2026-06-17 12:55:56

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel

New TALVEYÂ (talquetamab-tgvs) plus DARZALEX FASPROÂ (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combi

gurufocus.com - 2026-06-13 07:00:00

Large Impinj Investor Trims Position by $11.3 Million

Impinj connects physical items to the digital world with advanced RFID solutions; a key insider recently reduced their indirect holdings.

fool.com - 2026-06-05 16:11:39

Imagion Biosystems' IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review

[url="]Imagion Biosystems, Ltd. (ASX: IBX)[/url] has announced that the US Food and Drug Administration (FDA) completed its review of the company's investigati

gurufocus.com - 2026-06-02 12:00:00

Impinj (PI) Just Reclaimed the 200-Day Moving Average

After reaching an important support level, Impinj (PI) could be a good stock pick from a technical perspective. PI surpassed resistance at the 200-day moving average, suggesting a long-term bullish trend.

zacks.com - 2026-05-27 10:30:38

Impinj to Participate in Evercore Global TMT Conference

SEATTLE--(BUSINESS WIRE)--Impinj to Participate in Evercore Global TMT Conference.

businesswire.com - 2026-05-26 16:15:00

Impinj (PI) Just Flashed Golden Cross Signal: Do You Buy?

From a technical perspective, Impinj (PI) is looking like an interesting pick, as it just reached a key level of support. PI recently overtook the 20-day moving average, and this suggests a short-term bullish trend.

zacks.com - 2026-05-25 10:36:07

Is Impinj Inc (PI) Overvalued After 6.8% Rally? GF Value Says Overvalued

On May 22, 2026, Impinj Inc (PI) shares rose 6.8%, closing at $149.76. This positive movement comes amid a 52-week range that has seen a high of $247.06 and a l

gurufocus.com - 2026-05-22 18:50:00

Impinj Inc (PI) Stock Down 4.7% but Still Overvalued -- GF Score: 73/100

On May 19, 2026, Impinj Inc (PI) shares fell 4.7% today, bringing the current price to $132.74. The stock has experienced a 52-week range from a low of $87.36 t

gurufocus.com - 2026-05-19 19:39:00

This Beaten-Down Chip Stock Just Did Something It Hasn't Done in a Year. Time to Buy?

The catalyst lifted the chip stock to a 27% gain in the last two weeks.

fool.com - 2026-05-12 01:00:00

How Impinj Stock Jumped 20.5% Today

Impinj posted falling profits but still beat expectations. Here's why investors celebrated the report.

fool.com - 2026-04-30 17:54:11

This Chip Maker's Stock Is Soaring After Earnings. Analysts See 20% More Upside.

Chip maker Impinj is surging after beating earnings estimates and isuing better-than-expected second-quarter guidance.

barrons.com - 2026-04-30 11:10:00

Impinj, Inc. (PI) Q1 2026 Earnings Call Transcript

Impinj, Inc. (PI) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-04-29 19:51:32

Impinj (PI) Tops Q1 Earnings and Revenue Estimates

Impinj (PI) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.21 per share a year ago.

zacks.com - 2026-04-29 19:41:25

Impinj Reports First Quarter 2026 Financial Results

SEATTLE--(BUSINESS WIRE)--Impinj Reports First Quarter 2026 Financial Results.

businesswire.com - 2026-04-29 16:15:00

Get PI Insider Trade Alerts

PI Price Target Summary

Last Month

$0.00

0 analysts

Last Quarter

$165.00

3 analysts

Last Year

$195.17

18 analysts

All Time

$175.74

47 analysts

PI Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-05-01 Barclays Maintain Overweight Overweight
2026-04-30 UBS Maintain Neutral Neutral
2026-04-30 Needham Maintain Buy Buy
2026-04-30 Evercore ISI Group Maintain In Line In Line
2026-03-16 Barclays Maintain Overweight Overweight
2026-03-16 Roth Capital Maintain Buy Buy
2026-02-06 Evercore ISI Group Downgrade Outperform In Line
2026-02-06 Barclays Maintain Overweight Overweight
2026-02-06 Cantor Fitzgerald Maintain Overweight Overweight
2026-02-06 Needham Maintain Buy Buy
2026-02-06 Piper Sandler Maintain Overweight Overweight
2026-01-26 UBS Maintain Neutral Neutral
2026-01-16 Needham Maintain Buy Buy
2025-11-05 Barclays Maintain Overweight Overweight
2025-10-30 Cantor Fitzgerald Maintain Overweight Overweight
2025-10-30 Evercore ISI Group Maintain Outperform Outperform
2025-10-30 Needham Maintain Buy Buy
2025-10-23 Piper Sandler Maintain Overweight Overweight
2025-10-22 Susquehanna Maintain Positive Positive
2025-10-06 Cantor Fitzgerald Maintain Overweight Overweight
2025-09-15 Needham Maintain Buy Buy
2025-07-31 Needham Maintain Buy Buy
2025-07-31 Piper Sandler Maintain Overweight Overweight
2025-07-31 Cantor Fitzgerald Maintain Overweight Overweight
2025-07-23 Piper Sandler Maintain Overweight Overweight
2025-07-22 Susquehanna Maintain Positive Positive
2025-06-12 Piper Sandler Maintain Overweight Overweight
2025-04-24 Cantor Fitzgerald Maintain Overweight Overweight
2025-04-24 Needham Maintain Buy Buy
2025-04-24 Evercore ISI Group Maintain Outperform Outperform
2025-04-22 Piper Sandler Maintain Overweight Overweight
2025-02-06 Piper Sandler Maintain Overweight Overweight
2025-02-06 Needham Maintain Buy Buy
2025-02-06 Cantor Fitzgerald Maintain Overweight Overweight
2025-02-06 Goldman Sachs Maintain Neutral Neutral
2025-01-22 Susquehanna Maintain Positive Positive
2025-01-17 Needham Maintain Buy Buy
2024-10-25 Goldman Sachs Maintain Neutral Neutral
2024-10-24 Needham Maintain Buy Buy
2024-10-24 Cantor Fitzgerald Maintain Overweight Overweight
2024-10-24 Lake Street Maintain Buy Buy
2024-10-24 Piper Sandler Maintain Overweight Overweight
2024-10-24 Evercore ISI Group Maintain Outperform Outperform
2024-10-21 Susquehanna Maintain Positive Positive
2024-09-27 Piper Sandler Maintain Overweight Overweight
2024-07-26 Cantor Fitzgerald Maintain Overweight Overweight
2024-07-25 Cantor Fitzgerald Maintain Overweight Overweight
2024-07-25 Lake Street Maintain Buy Buy
2024-07-25 Needham Maintain Buy Buy
2024-07-25 Roth MKM Maintain Buy Buy
2024-07-25 Evercore ISI Group Maintain Outperform Outperform
2024-07-17 Susquehanna Maintain Positive Positive
2024-07-11 Piper Sandler Maintain Overweight Overweight
2024-06-05 Needham Maintain Buy Buy
2024-05-20 Goldman Sachs Downgrade Buy Neutral
2024-05-16 Needham Maintain Buy Buy
2024-04-26 Goldman Sachs Maintain Buy Buy
2024-04-25 Piper Sandler Maintain Overweight Overweight
2024-04-25 Needham Maintain Buy Buy
2024-04-25 Susquehanna Maintain Positive Positive
2024-04-25 Roth MKM Maintain Buy Buy
2024-04-23 Susquehanna Maintain Positive Positive
2024-03-14 Canaccord Genuity Maintain Buy Buy
2024-03-14 Needham Maintain Buy Buy
2024-03-14 Roth MKM Maintain Buy Buy
2024-02-09 Goldman Sachs Maintain Buy Buy
2024-02-09 Roth MKM Maintain Buy Buy
2024-02-09 Susquehanna Maintain Positive Positive
2024-02-09 Needham Maintain Buy Buy
2024-01-18 Needham Maintain Buy Buy
2023-10-26 Goldman Sachs Maintain Buy Buy
2023-10-26 Needham Maintain Buy Buy
2023-10-26 Roth MKM Maintain Buy Buy
2023-07-27 Needham Maintain Buy Buy
2023-06-15 Roth MKM Maintain Buy Buy
2023-06-15 Needham Maintain Buy Buy
2023-04-28 Goldman Sachs Maintain Buy Buy
2023-04-27 Needham Maintain Buy Buy
2023-04-27 Lake Street Maintain Buy Buy
2023-04-27 Piper Sandler Maintain Overweight Overweight
2023-04-27 Roth Capital Maintain Buy Buy
2023-04-27 Roth MKM Maintain Buy Buy
2023-04-19 Needham Maintain Buy Buy
2023-02-10 Goldman Sachs Maintain Buy Buy
2023-02-09 Canaccord Genuity Maintain Buy Buy
2023-02-09 Needham Maintain Buy Buy
2023-01-27 Piper Sandler Maintain Overweight Overweight
2023-01-12 Jefferies Maintain Buy Buy
2023-01-12 Needham Maintain Buy Buy
2022-12-05 Goldman Sachs Maintain Buy Buy
2022-10-27 Goldman Sachs Maintain Buy Buy
2022-10-27 Needham Maintain Buy Buy
2022-07-28 Goldman Sachs Maintain Buy Buy
2022-07-28 Needham Maintain Buy Buy
2022-07-28 Piper Sandler Maintain Overweight Overweight
2022-04-28 Piper Sandler Maintain Overweight Overweight
2022-03-28 Goldman Sachs Maintain Buy Buy
2022-01-12 Needham Maintain Buy Buy
2022-01-12 Canaccord Genuity Maintain Buy Buy
2021-12-15 Jefferies Maintain Buy Buy
2021-11-17 Canaccord Genuity Maintain Buy Buy
2021-10-28 Needham Maintain Buy Buy
2021-10-26 Lake Street Maintain Buy Buy
2021-07-29 Needham Maintain Buy Buy
2021-04-29 Needham Maintain Buy Buy
2021-02-11 Needham Maintain Buy Buy
2021-02-11 Piper Sandler Maintain Overweight Overweight
2021-02-11 Morgan Stanley Maintain Equal Weight Equal Weight
2021-02-11 Canaccord Genuity Maintain Buy Buy
2021-01-19 Morgan Stanley Maintain Equal Weight Equal Weight
2021-01-19 Needham Maintain Buy Buy
2020-12-14 Morgan Stanley Maintain Equal Weight Equal Weight
2020-11-30 Goldman Sachs Maintain Buy Buy
2020-10-29 Piper Sandler Maintain Overweight Overweight
2020-10-29 Canaccord Genuity Maintain Buy Buy
2020-07-30 Piper Sandler Maintain Overweight Overweight
2020-07-30 Morgan Stanley Maintain Equal Weight Equal Weight
2020-07-30 Needham Maintain Buy Buy
2020-07-10 Needham Maintain Buy Buy
2020-06-16 Morgan Stanley Maintain Equal Weight Equal Weight
2020-04-28 Needham Maintain Buy Buy
2020-04-27 Morgan Stanley Maintain Equal Weight Equal Weight
2020-03-30 Morgan Stanley Maintain Equal Weight Equal Weight
2020-03-19 Needham Maintain Buy Buy
2020-03-18 Morgan Stanley Maintain Equal Weight Equal Weight
2020-03-04 RBC Capital Maintain Sector Perform Sector Perform
2020-01-21 Needham Maintain Buy Buy
2019-12-17 Needham Upgrade Hold Buy
2019-07-30 Piper Jaffray Maintain Overweight Overweight
2019-07-30 Piper Sandler Maintain Overweight Overweight
2019-07-01 Dougherty Upgrade Neutral Buy
2019-07-01 Dougherty & Co. Upgrade Neutral Buy
2018-05-08 Canaccord Genuity Upgrade Hold Buy
2018-02-15 Canaccord Genuity Maintain Hold Hold
2018-02-06 PiperJaffray Upgrade Neutral Overweight
2018-02-06 Piper Sandler Upgrade Neutral Overweight
2018-02-05 Morgan Stanley Maintain Equal Weight Equal Weight
2018-02-02 Piper Sandler Maintain Neutral Neutral
2018-02-02 Canaccord Genuity Downgrade Buy Hold
2018-02-02 PiperJaffray Maintain Neutral Neutral
2018-02-02 RBC Capital Downgrade Outperform Sector Perform
2017-12-13 Morgan Stanley Maintain Equal Weight Equal Weight
2017-11-02 PiperJaffray Downgrade Overweight Neutral
2017-11-02 Piper Sandler Downgrade Overweight Neutral
2017-11-02 Canaccord Genuity Maintain Buy Buy
2017-11-02 Morgan Stanley Maintain Equal Weight Equal Weight
2017-08-04 Canaccord Genuity Maintain Buy Buy
2017-06-27 Pacific Crest Downgrade Overweight Sector Weight
2017-06-19 Morgan Stanley Downgrade Overweight Equal Weight
2017-02-23 Morgan Stanley Maintain Overweight Overweight
2016-09-26 KeyBanc Maintain Overweight Overweight
2016-09-26 Keybanc Maintain Overweight Overweight
2016-08-15 RBC Capital Maintain Outperform Outperform
2016-08-15 PiperJaffray Maintain Overweight Overweight
2016-08-15 Pacific Crest Maintain Overweight Overweight
2016-08-15 Needham Maintain Buy Buy
2016-08-15 Canaccord Genuity Maintain Buy Buy